Treatment of Autoimmune Alopecia (Alopecia Areata)
For limited patchy alopecia areata (<50% scalp involvement), intralesional corticosteroids with triamcinolone acetonide (5-10 mg/mL) are the first-line treatment, while severe disease (≥50% scalp involvement) now requires oral JAK inhibitors as first-line therapy, with baricitinib or ritlecitinib being FDA-approved options. 1, 2
Treatment Algorithm Based on Disease Severity
Mild-to-Moderate Disease (SALT <50%)
First-Line Options:
Intralesional corticosteroids are most effective for limited patchy disease
- Use triamcinolone acetonide 5-10 mg/mL or hydrocortisone acetate 25 mg/mL
- Inject 0.05-0.1 mL just beneath the dermis in upper subcutis
- Each injection produces ~0.5 cm diameter tuft of hair growth
- Repeat monthly injections
- Best results: Patients with fewer than 5 patches <3 cm diameter (62% achieved full regrowth) 1
- Particularly suitable for cosmetically sensitive areas like eyebrows 1
Topical corticosteroids as alternative
- Clobetasol propionate 0.05% foam or ointment
- Apply under occlusive dressing 6 out of 7 nights for 6 months if using ointment
- Caveat: Evidence is limited; folliculitis is common side effect 1
Observation alone is legitimate for very limited disease
- Up to 80% spontaneous remission in limited patchy hair loss <1 year duration
- Advise patients regrowth takes minimum 3 months per patch 1
Severe Disease (SALT ≥50%)
First-Line: Oral JAK Inhibitors - These have fundamentally changed the treatment landscape 3, 2
FDA-Approved Options:
- Ritlecitinib (JAK3/TEC inhibitor): Approved for ages ≥12 years 2, 4
- Baricitinib (JAK1/2 inhibitor): Approved for adults ≥18 years 2, 4
- Deuruxolitinib: Also FDA-approved option 3
Selection criteria between JAK inhibitors:
- Patient age (ritlecitinib if adolescent)
- Safety profile considerations
- Comorbidities
- Laboratory monitoring requirements
- Insurance coverage 3
Expected outcomes: ~30-40% achieve clinically meaningful hair regrowth, but ~30% are non-responders 5
Important caveat: Switching between JAK inhibitors may still benefit patients who don't respond to initial agent 3
Alternative Systemic Therapies (Off-Label)
For patients who cannot access or tolerate JAK inhibitors:
Contact immunotherapy (DPCP/SADBE): Effective but requires specialized protocols
- DPCP preferred (more stable than SADBE)
- Sensitize with 2% solution, then weekly applications starting at 0.001%
- Increase concentration until mild dermatitis achieved
- Must store in dark; patients wear hat/wig for 24 hours post-application 1
Systemic corticosteroids (oral dexamethasone): Shows highest efficacy in network meta-analysis (95.9% SUCRA rank) but significant safety concerns 6
Other immunosuppressants: Cyclosporine, methotrexate, azathioprine (off-label) 2
Oral minoxidil: Adjuvant therapy only, limited efficacy data 2
Critical Management Principles
No treatment alters the long-term course of disease - all therapies induce hair growth but don't prevent future episodes 1
Relapse is common:
- Can occur during treatment, after dose reduction, or after discontinuation 5
- Warn patients upfront about relapse potential to manage expectations 1
Prognosis considerations:
- Longstanding extensive alopecia has poor prognosis
- Wigs may be better option than ineffective treatments in severe chronic cases 1
Emerging approach: Sequential therapy with JAK inhibitor followed by low-dose IL-2 may induce sustained remission by restoring immune tolerance, though this requires further validation 7
Safety ranking (from network meta-analysis): Ritlecitinib and baricitinib have superior safety profiles compared to systemic steroids and contact immunotherapy, making them preferable long-term options despite moderate efficacy 6